• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·600594.SS
Share

Guizhou Yibai Pharmaceutical Co., Ltd. Stocks

CN¥ 3.57Last Updated 12.10.2026

Issuer Rating

4/7
Performance

Modest

Risk

Limited

Recommendation

Hold

Market Cap

CN¥ 435.48M

CN¥ 3.57
Key Takeaways

Risk factor

Fair trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Guizhou Yibai Pharmaceutical Co., Ltd. is a Chinese pharmaceutical enterprise that encompasses the full spectrum of activities from researching and developing new drugs to their production and commercialization throughout the country. The company offers a diverse portfolio of medications, available in various dosage forms including capsules, tablets, granules, syrups, liquid injectables (small-volume), lyophilized powder injections, traditional pills, and oral solutions. These therapeutic agents are designed to address a broad range of medical conditions, specifically targeting oncology, cerebrovascular health, respiratory ailments, rheumatic diseases, digestive disorders, pediatric and gynecological illnesses, alongside providing anti-infective, anti-inflammatory, and pain management solutions. Established in 1995, the company maintains its headquarters in Guiyang, China.

Company Valuation

Slightly overvalued
3/7

From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks. In particular, the stock is overvalued on P/FCF.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

12.10.2026 12:54

After Anthropic backed out of the deal, Amazon began considering a $7 billion acquisition of an AI startup

12.10.2026 12:04

Burry adjusted his bets on a market decline. Which stocks did he buy and sell?

12.10.2026 11:06

Oil prices fell after Trump's remarks about an "energy truce" between Russia and Ukraine

12.10.2026 10:45

The Hong Kong market is under pressure. Which stocks did the investor from “Shorting the Market” buy?

12.10.2026 10:38

Top Stories This Morning: Oil Prices Fall Following Trump's Statement; Amazon Shows Interest in Decart

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026